Table 1.
Clinical and laboratory manifestations of COVID-19 patients with facial palsy
| Patient | Age | Gendera | Clinical manifestation (House-Brackmann grading scale) | First symptomb | CSFc | Imaging | Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|
| 1 | 43 | F | Right facial palsy (3) | Yes | - | CT scan: normal | Oral steroids | Partial |
| 2 | 25 | F | Right facial palsy (2) | Yes | 5–29–50 | MRI: normal | Oral steroids + acyclovir | Complete |
| 3 | 33 | F | Right facial palsy (3) | Yes | - | - | Oral steroids + acyclovir | Partial |
| 4 | 26 | F | Left facial palsy (2) | No | 4–31–55 | MRI: left facial nerve enhancement | Oral steroids | Complete |
| 5 | 50 | F | Left facial palsy (3) | No | 3–50–56 | CT scan: normal | Oral steroids | Partial |
| 6 | 38 | F | Left facial palsy (2) | No | 1–28–51 | MRI: normal | Supportive | Complete |
| 7 | 39 | F | Right facial palsy (2) | No | 1–32–38 | MRI: normal | Oral steroids | Complete |
| 8 | 34 | M | Left facial palsy (2) | No | 2–33–91 | MRI: normal | Intravenous steroids | Complete |
aGender: F female, M male
bFacial palsy as first COVID-19 symptom/signal
cCerebrospinal fluid analysis: cell count/mm3—protein level mg/dl—glucose level mg/dl